1. Introduction
Syphilis and human immunodeficiency virus (HIV), two of the most prevalent sexually transmitted infections (STIs) worldwide, continue to pose significant public health challenges [1,2,3]. Individually, each infection carries its own set of complexities, yet when co-existing within the same individual, they can amplify the severity of their respective clinical outcomes and transmission risks [4]. The co-occurrence of syphilis and HIV presents unique challenges due to the complex interaction between these two infections [5]. Understanding the interplay between syphilis and HIV is crucial for effective prevention, diagnosis, and management strategies [5,6]. Syphilis can increase the risk of HIV acquisition and transmission through genital ulcers, while HIV infection and antiretroviral therapy (ART) can alter the natural history and clinical presentation of syphilis [7,8,9,10]. Furthermore, the immunosuppressive effects of HIV can complicate the diagnosis and treatment of syphilis, leading to atypical manifestations and potential treatment failures [10,11,12]. Cutaneous secondary syphilis, known as the “great imitator”, may present in atypical forms in people with HIV (PWH), such as lupus vulgaris and purulent dermatitis [13,14]. Addressing the threat of drug resistance, syphilis requires a multifaceted approach, including enhanced surveillance, antimicrobial stewardship, and consideration of alternative treatment regimens [15,16].
The observed rates of syphilis have been on a substantial rise globally over the last two decades [17]. The resurgence of syphilis rates since 2000 might be attributed to several interconnected factors, including changes in sexual behavior and decreased awareness and fear of HIV and acquired immunodeficiency syndrome (AIDS) [18]. With the advent of ART for HIV/AIDS in the late 20th century, the perception of HIV/AIDS shifted from a terminal illness to a manageable chronic condition [19]. Prolonged survival from HIV infection, the concept of U = U (undetectable = untransmittable), and the initiation of PrEP (Pre-Exposure Prophylaxis) may have led to increased risky sexual behaviors, including higher rates of unprotected condomless sex, multiple sexual partners, and the rise of anonymous sexual encounters facilitated by dating apps and online platforms [18,19,20]. Certain population groups are disproportionately affected by syphilis, including men who have sex with men (MSM), transgender individuals, PWH, and people injecting drugs [4,17,21]. However, sporadic outbreaks of syphilis have also been reported among pregnant women, commercial sex workers, and heterosexual individuals experiencing socioeconomic disadvantage [1,2].
In 2022, there was a crude notification rate of 8.5 syphilis cases per 100,000 people in the European Union (EU) region, representing a 41% increase compared to 2018 and reaching an all-time high since 2013, according to the annual epidemiological surveillance report from European Centre for Disease Prevention and Control (ECDC) [2]. Three-quarters of cases were reported in MSM, showing a steep increase in this transmission group during the last decade [2]. A total of 26% of the MSM cases with information on HIV status were people with HIV co-infection. Greece was among the countries with the highest rates of confirmed syphilis cases in the EU (≥7 cases per 100,000 people) and also the highest observed male-to-female ratio (above 10:1) [2].
Penicillin is the reference standard in syphilis treatment; however, it is often commercially unavailable in Greece, and healthcare providers should consider alternative treatment options [22]. In most cases, doxycycline is used as a substitute antibiotic based on the stage of syphilis and individual patient factors [22]. The aim of this study is to investigate the rates of incident syphilis in PWH with high-risk sexual behavior during the prepandemic period and the COVID-19 era, delineate its stages (primary, secondary, latent, tertiary, neurosyphilis), assess sociodemographic factors influencing its occurrence, and examine treatment options and efficacy utilized in affected individuals.
2. Materials and Methods
2.1. Study Design
This was a retrospective, single-center cohort study conducted at AHEPA University General Hospital of Thessaloniki. Our Department of Infectious Diseases currently provides follow-up care every 6 to 8 months for approximately 1800 PWH. Serological tests for syphilis are routinely performed on individuals engaging in high-risk sexual behavior, including those with a history of syphilis, other STIs, multiple sexual partners, and those who do not consistently use protection during sex. PWH exhibiting high-risk sexual behavior who attended outpatient clinical care between 1 January 2019 and 31 December 2022 were enrolled in the study.
Sociodemographic and epidemiological data were obtained through the electronic medical record system and clinical visits. This information included gender, age, ethnicity, mode of HIV transmission, duration of HIV infection, duration of ART, and history of syphilis. HIV RNA plasma levels were quantified using real-time PCR, with the lower limit of detection set at 20 copies/mL, and CD4+ T-cell counts were determined by flow cytometry. Suppressed viral load was considered as HIV RNA < 50c/mL. The serological tests for syphilis included a treponemal test using chemiluminescence immunoassay (CIA) and a non-treponemal test using Rapid Plasma Reagin test (RPR). We used the reverse syphilis screening algorithm, with the primary screening test performed using the CIA test. In case of positive CIA test, quantitative RPR test was used to determine serological activity of syphilis and monitor the effect of treatment in accordance with 2024 Centers for Disease Control and Prevention (CDC) laboratory recommendations for syphilis testing, 2021 CDC treatment guidelines on sexually transmitted infections, and 2020 European guideline on the management of syphilis [22,23,24].
This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the local Ethics Committee under protocol number 21482/24.
2.2. Definition of Incident Syphilis and Stages
Incident syphilis was defined by a new seroconversion of CIA test or a fourfold or greater increase in RPR test titers in a person with known previous history of syphilis. The definition of syphilis stages was established based on clinical findings. Cerebrospinal fluid evaluation was performed only in persons with clinical signs of neurosyphilis (e.g., cranial nerve dysfunction, meningitis) according to recent guidelines, and further ocular and otic examination was warranted for those with ocular symptoms and auditory abnormalities, respectively [22]. We defined latent syphilis as the presence of seroreactivity with no clinical evidence of primary, secondary, or tertiary disease. Early latent syphilis was considered when infection occurred within the last 12 months, as documented by a negative treponemal test within 1 year of a syphilis diagnosis or a fourfold or greater increase in RPR titers within 1 year of previous testing. Late latent syphilis (>1 year’s duration) was assumed in an asymptomatic individual with positive syphilis serology if they did not meet the criteria for early latent syphilis.
2.3. Syphilis Treatment
PWH diagnosed with primary, secondary, and early latent syphilis were treated with benzathine penicillin G (BPG) 2.4 million units intramuscularly (IM) in a single dose as the first-line therapy, whereas participants diagnosed with late latent syphilis received 3 doses of BPG 2.4 million units IM at 1-week intervals. In case of penicillin shortage or history of allergy or intolerance, we used doxycycline as an alternative regimen. The dosage of doxycycline was 100 mg orally twice a day for 14 days for the treatment of primary, secondary, and early latent syphilis and 100 mg orally twice a day for 28 days for the treatment of late latent syphilis. Intravenous ceftriaxone was used for the treatment of neurosyphilis due to penicillin allergy.
2.4. Treatment Response
Serological evaluation was performed at 6 and 12 months after treatment. An adequate therapeutic response was defined by the complete loss of nontreponemal antibodies or a fourfold decline in RPR titers, equivalent to a change of two dilutions, at 12th month. Definition of serological nonresponse and treatment failure included a lack of a fourfold decrease in RPR titers at 12 months after treatment and a sustained (>2 weeks) fourfold increase in nontreponemal test titers at any time after treatment or recurrence or persistence of symptoms, respectively. In instances of treatment failure, participants were queried regarding the potential for syphilis reinfection and were subsequently excluded from the study if they engaged in risky sexual behavior.
2.5. Statistical Analysis
Quantitative data were checked for normality using the Shapiro–Wilk test and are reported as median and interquartile range (IQR). Qualitative data are presented as numbers and percentages. Fisher’s exact test and Pearson’s chi-square test were employed to assess associations between categorical variables, as appropriate. The non-parametric Mann–Whitney U test and Kruskal–Wallis test were utilized for comparisons between two or more groups, respectively. Post hoc testing with Dunn’s test was conducted for multiple comparisons. Bivariate and multivariable logistic regression analyses were used to predict new syphilis diagnoses. Factors with a p-value ≤ 0.25 in the univariable analysis were included in the multivariable analysis. The level of significance was set at a p-value of less than 0.05. Data were analyzed using IBM SPSS Statistics 26.0 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Baseline Characteristics of Study Participants
A total of 1896 syphilis tests were conducted on 991 PWH during the study period. The vast majority of the study participants were Greek males (Table 1). The main mode of transmission involved MSM (64.7%). The median age at baseline was 41.3 (34.3–49.7) years, and the median duration of HIV infection was 4.7 (0.3–10.3) years. A total of 320 (32.3%) participants had a history of previous syphilis infection (48.8% of the tests performed), as indicated by positive treponemal antibody testing. The MSM population exhibited the highest rate of positive syphilis history (41.3%) compared to the other transmission risk groups (15.6%) (χ2(1) = 69.3, p < 0.001, Pearson’s chi-square test). A total of 249 participants were tested for syphilis after being recently diagnosed with HIV infection and during their initial referral to our Infectious Diseases unit. The median CD4+ T-cell count was 670 (483–882) cells/mm3, and HIV viral load was undetectable (<50 copies/mL) in 81.5% of the syphilis tests conducted.
3.2. Rate of Syphilis Testing
Throughout the entire follow-up period, 436 (44%), 240 (24.2%), and 123 (12.4%) participants were tested at least two, three, and four times for syphilis, respectively. Syphilis testing was conducted at least twice for 54.9% of individuals in the MSM group, 35.4% of PWH with unknown transmission risk, 22.9% of heterosexuals, and 17.5% of PWID. There was a progressive rise in the frequency of syphilis testing over the years of the study (Table 2). Men underwent syphilis testing per person at a higher rate compared to women (U = 27,700, p < 0.001). Greek PWH were tested more frequently than non-Greek PWH (U = 35,821, p < 0.001). Compared with heterosexuals, PWID, and those with unknown transmission risk, MSM had a statistically significant higher rate of syphilis testing (H(3) = 94.5, p < 0.001). The rates of testing were lower among PWID. No variation was noted in the frequency of syphilis testing based on age groups (H(4) = 5.1, p < 0.282).
3.3. Rate of Incident Syphilis
A total of 107 incident syphilis cases (5.6% of tests), all in males, were identified in 94 PWH (9.4% of study participants); 82 of them had one, 11 had two, and 1 had three episodes of syphilis during the study period. The occurrence of syphilis exhibited a decline in 2020 compared to 2019, followed by a gradual rise until 2022 (Table 2, Figure 1). A total of 99 (92.5%) of the syphilis episodes occurred in Greek people and 97 (90.5%) in MSM. The median age of the newly diagnosed syphilis cases was 37.6 (31.8–46.8) years. Seventeen participants (6.8%) with recently diagnosed HIV infection were also found to have syphilis coinfection during their initial clinical visit.
3.4. Sociodemographic and HIV-Related Predictors of Incident Syphilis Cases
Compared to other transmission risk groups, MSM were more likely to be co-infected with syphilis at the time of HIV diagnosis (OR: 7.02, 95%CI: 1.57, 31.35, p = 0.011). Similarly, MSM were more likely to contract syphilis during the study period compared to other modes of transmission (Table 3). There was a positive association between younger age and the likelihood of syphilis diagnosis. Among age groups, PWH aged 30–39 had the highest rate of incident syphilis, while PWH aged over 60 years had the lowest. The duration of HIV infection, duration of ART, nationality, CD4+ T-cell count, detectable HIV viral load, and history of previous syphilis infection did not show any association with the development of syphilis. Excluding male sex, MSM were the only independent predictors of the occurrence of new syphilis cases in the multivariable logistic regression model (χ2(8) = 33.6, p < 0.001) (Table 3).
3.5. Stages of Syphilis
The majority (71.1%) of incident syphilis cases were classified as latent syphilis, 18.7% were secondary syphilis, 9.3% were primary syphilis, and one case (0.9%) of neurosyphilis was observed (Table 4). Out of the 76 cases of asymptomatic latent syphilis, 51 (67%) were classified as late latent syphilis, with the remaining cases categorized as early latent syphilis.
3.6. Treatment Efficacy
A total of 92 PWH (86%) received treatment with BPG, 14 PWH (13.1%) were treated with doxycycline, and the case of neurosyphilis was treated with ceftriaxone. Treatment success, defined by adequate serologic response at the 12th month, was observed in 89 out of 92 PWH (96.7%) who received penicillin, as well as in 13 out of 14 PWH (92.9%) who were treated with doxycycline (Table 4). The remaining four cases were serological non-responders who did not achieve a fourfold decline in RPR titer. No treatment failure was observed. There was no statistically significant difference in effectiveness observed between the two treatments (p = 0.438, Fisher’s exact test). The treatment of neurosyphilis with ceftriaxone was also successful. No adverse drug effects were observed in any treatment.
4. Discussion
This study observed that nearly one in ten PWH engaging in risky sexual behaviors developed syphilis during a four-year monitoring period. Furthermore, approximately one-third of the study participants had experienced at least one syphilis episode in the past. This significant rate of syphilis diagnosis aligns with findings from other recent studies [25,26,27]. This trend may be attributed to an increased proportion of individuals engaging in unprotected sex due to reduced concerns about STIs, including HIV infection [18,20]. The shift toward viewing HIV infection as a manageable chronic condition has inadvertently led to decreased emphasis on safe sex among certain populations, resulting in higher rates of new HIV diagnoses and co-infections with syphilis [19,28].
STI surveillance data from the COVID-19 pandemic period must be interpreted with caution due to significant disruptions in access to public health services, particularly during lockdowns, which often affected routine preventive screening for STIs. Despite these challenges, a global increase in syphilis incidence was noted during the pandemic. While the CDC and other studies indicated a rise in syphilis cases as early as 2020 compared to 2019, data from the ECDC initially showed a decline in syphilis diagnoses in 2020, followed by a rapid increase in 2021 and 2022 [1,2,29,30,31]. Our study aligns with the findings of the ECDC report. In 2020, we observed an approximately 50% decline in the number of syphilis diagnoses compared to 2019, followed by a gradual increase over the subsequent two years, although it did not reach the levels of 2019. Importantly, outpatient care for PWH in our department remained largely unaffected during the COVID-19 period, as evidenced by patient turnout and the consistently high number of tests conducted. The decline in syphilis rates in 2020 may have been influenced by a significant portion of the Greek population adhering to pandemic prevention measures and reducing social contacts during the initial months of the COVID-19 period, a trend that waned in the following period.
We found that all cases of syphilis involved males, predominantly younger MSM. A notable proportion of these cases appeared to be reinfections during the study period. MSM and individuals with unknown transmission risk had a higher rate of syphilis diagnosis compared to heterosexuals and PWID. Furthermore, the incidence of previous syphilis infection and the likelihood of co-infection with syphilis at the time of HIV diagnosis was significantly higher among MSM than in the other transmission groups. MSM are disproportionately affected by STIs such as gonorrhea and primary and secondary syphilis [1,2]. Co-infection with HIV is prevalent among this group, with recent data in EE showing that 26% of MSM diagnosed with syphilis also had HIV [2]. This percentage is higher among individuals with primary and secondary syphilis. The factors associated with the rising incidence of syphilis among MSM include living with HIV, having a higher number of non-steady male partners engaging in condomless anal intercourse, longer intervals between STI screenings, involvement in sex work, and the use of PrEP for HIV prevention [2,17].
The prevalence of syphilis stages varies among different studies [32]. We noted that the majority of syphilis cases involved latent stages, with only one case presenting as neurosyphilis. The presence of asymptomatic syphilis should not offer reassurance to affected individuals; rather, it should raise significant concerns. If left untreated, latent syphilis can progress to tertiary syphilis or neurosyphilis [22]. From a public health perspective, pregnant women with latent syphilis can also transmit Treponema pallidum to their fetus, and individuals with early latent syphilis can unwittingly transmit the disease to sexual partners through recently healed lesions, thereby contributing to the community-wide transmission of syphilis [22,33]. Therefore, early detection and treatment of syphilis are crucial for preventing serious complications and reducing transmission rates.
Effective prevention strategies should focus on promoting regular STI screening, including syphilis, addressing barriers to condom use, providing comprehensive sexual health education, and ensuring access to PrEP and other prevention tools while also promoting safe sexual practices [1,34,35]. Identifying cases through enhanced screening of PWH who are at risk, along with incorporating syphilis testing into routine HIV clinical monitoring, is essential [1,34,35]. Addressing these factors comprehensively can help mitigate the rising incidence of syphilis within PWH.
We did not identify any significant correlations between incident syphilis cases and HIV-related characteristics, including the duration of HIV infection, the duration of ART, CD4+ T-cell count, and HIV viral load > 50 c/mL. Although there are studies suggesting that syphilis may increase viral load levels and decrease CD4+ T lymphocytes, the data are contradictory [36]. This is partly due to the lack of consensus among studies and also because these disruptions may be temporary [37,38]. It is more evident that ART improves the outcome of syphilis by reducing neurosyphilis episodes through immunological restoration and enhancing treatment effectiveness [9]. Since most PWH were receiving ART, this could partly explain the lower incidence of neurosyphilis in our study.
The treatment of choice for all stages of syphilis (excluding neurosyphilis) in PWH remains intramuscular BPG, with reported rates of serological response ranging from 70% to 95% in the international literature [22,32]. Alternative treatment options include doxycycline and ceftriaxone [22]. In our clinic, we typically treat syphilis with BPG. If penicillin is not available or if there is a history of documented allergy, we administer doxycycline. The majority of study participants (86%) received penicillin. A total of 96.3% of total syphilis cases (103 out of 107) exhibited a serological response 12 months after starting treatment. We found no statistically significant difference in effectiveness between BPG and doxycycline, suggesting that doxycycline is a viable alternative option. The need for new antimicrobial agents is an ongoing domain of discussion and research [15,16]. While penicillin remains highly effective for syphilis, the exploration of new treatments is motivated by factors such as penicillin shortages, patient inconvenience with multiple injections, and allergies [32]. There have been reports of penicillin-resistant strains of syphilis, although they are still relatively rare [39]. A recent systematic review and meta-analysis of 27 studies showed that monotherapy with penicillin did not outperform other monotherapies, such as doxycycline, ceftriaxone, and azithromycin, in terms of serological conversion [32]. This suggests a potential to reduce global reliance on penicillin, including for PWH, when it is unavailable. Likewise, since there is no vaccine for syphilis, post-exposure prophylaxis with doxycycline (Doxy-PEP) has been extensively studied in recent years, and its effectiveness has been demonstrated in numerous studies [40,41]. However, its use as an alternative to the currently recommended prophylactic treatment with penicillin within 90 days of exposure has not yet been widely adopted due to concerns about the potential impact on antimicrobial resistance and the microbiome [42,43].
This study has several limitations. Firstly, it is a single-center study that focuses solely on PWH, and there is no control group without HIV infection for comparison. Additionally, the participants were predominantly male PWH, reflecting the male-dominated composition of PWH monitored in our department. Therefore, our findings may not be generalizable across genders. The interval between syphilis testing varied among participants, and there were occasional dropouts during the study. Furthermore, individuals living with HIV can also undergo syphilis and STI testing outside of HIV care at other sexual health clinics, potentially resulting in an underestimation of the diagnosis rate of incident syphilis cases. It is possible that some cases of syphilis were missed due to false-negative RPR tests and the reduced sensitivity of the nontreponemal tests in defining incident syphilis cases. Similarly, some cases of asymptomatic neurosyphilis may have been missed because not all participants underwent a lumbar puncture. Finally, the high ratio of penicillin to doxycycline (6.7:1) in the treatment of syphilis, along with the small number of cases that received doxycycline, may potentially limit the conclusions when comparing the effectiveness between the two treatments.
Our study stands as one of the scarce inquiries into the prevalence and treatment response of syphilis among PWH in Greece. Further studies need to be conducted to provide useful data and promote public health.
5. Conclusions
In conclusion, our study underscores a concerning incidence of syphilis among PWH engaging in high-risk sexual behavior, particularly among younger MSM. Regular screening and comprehensive sexual health education are essential for early detection and treatment to prevent disease progression and transmission. BPG remains the preferred treatment option, but alternative regimens such as doxycycline have shown positive outcomes, highlighting the importance of flexibility in treatment approaches to accommodate penicillin shortages, allergies, and patient preferences.
Conceptualization, S.N., D.P. and S.M.; methodology, D.P. and O.T.; validation, T.T., M.C. and K.K.; formal analysis, S.N., K.M., M.C. and T.T.; investigation, S.N., E.P. and K.K.; data curation, S.N., K.K., E.P., K.M. and K.P.; writing—original draft preparation, S.N., D.P. and T.C.; writing—review and editing O.T., S.M., K.P. and E.P.; visualization, T.C., P.K., E.P. and K.M.; supervision, T.C., O.T., P.K. and E.P.; project administration, O.T. and S.M. All authors have read and agreed to the published version of the manuscript.
All data generated in this study are included in this published article. Further inquiries can be directed to the corresponding author.
The authors declare no conflicts of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Demographic and clinical characteristics of PWH at baseline (n = 991).
| Characteristics | Result |
|---|---|
| Gender, n (%) | |
| Male | 900 (90.8) |
| Female | 91 (9.2) |
| Age in years, median (IQR) | 41.3 (34.3–49.7) |
| Age in years, n (%) | |
| 16–29 | 153 (15.4) |
| 30–39 | 286 (28.9) |
| 39–49 | 310 (31.3) |
| 50–59 | 180 (18.2) |
| >60 | 62 (6.3) |
| Mode of transmission, n (%) | |
| MSM | 641 (64.7) |
| Heterosexual | 141(14.2) |
| PWID | 122 (12.3) |
| MSM + PWID | 4 (0.4) |
| Unknown/Other | 83 (8.4) |
| Ethnicity, n (%) | |
| Greek | 874 (88.2) |
| Other | 117 (11.8) |
| Duration of HIV infection in years, median (IQR) | 4.7 (0.3–10.3) |
| Duration of HIV infection in years, n (%) | |
| 0–1 | 317 (32) |
| 1–5 | 191 (19.3) |
| 5–10 | 225 (22.7) |
| >10 | 258 (26) |
| Initial referral to IDU, n (%) | 249 (25.1) |
| Duration of ART in years, median (IQR) | 3.3 (0–8) |
| CD4+ T cell count, cell/mm3, median (IQR) | 594 (391–814) |
| CD4+ T cell count < 200 cell/mm3, n (%) | 90 (9.1) |
| HIV RNA < 50 c/mL, n (%) | 704 (71) |
| History of syphilis, n (%) | 320 (32.3) |
| MSM | 265 (41.3) |
| Heterosexual | 21 (14.9) |
| PWID | 14 (11.5) |
| MSM + PWID | 0 (0) |
| Unknown/Other | 20 (24.1) |
PWH, people with HIV; n, number; IQR, interquartile range; MSM, men who have sex with men; PWID, people who inject drugs; HIV, human immunodeficiency virus; IDU, infectious diseases unit; ART, antiretroviral therapy; CD4, cluster of differentiation 4.
Syphilis diagnoses and syphilis testing by year.
| Variable | Year | Total | |||
|---|---|---|---|---|---|
| 2019 | 2020 | 2021 | 2022 | ||
| Syphilis cases | 35 | 18 | 25 | 29 | 107 |
| Syphilis tests | 398 | 410 | 496 | 592 | 1896 |
| PWH tested for syphilis | 362 | 384 | 395 | 532 | 1673 |
PWH, people with HIV.
Characteristics of incident syphilis cases and bivariate and multivariable regression models for new syphilis diagnosis.
| Characteristics | Incident syphilis (n = 107) | Crude OR | p | Adjusted OR | p |
|---|---|---|---|---|---|
| Age in years, median (IQR) | 37.6 (31.8–46.8) | 0.97 (0.96, 0.99) | 0.004 | 0.98 (0.96, 1.003) | 0.091 |
| Age in years, n | |||||
| 16–29 | 19 | 1.79 (0.98, 3.28) | 0.06 | ||
| 30–39 | 40 | 1.83 (1.11, 3.02) | 0.019 | ||
| 40–49 | 27 | Ref | |||
| 50–59 | 17 | 1.1 (0.59, 2.04) | 0.775 | ||
| >60 | 4 | 0.79 (0.27, 2.29) | 0.66 | ||
| Ethnicity, n | |||||
| Greek | 99 | 0.86 (0.41, 1.8) | 0.679 | ||
| Other | 8 | Ref | |||
| Mode of transmission, n | |||||
| MSM | 97 | 5.12 (1.61, 16.29) | 0.006 | 4.4 (1.36, 14.24) | 0.013 |
| Heterosexual | 3 | Ref | Ref | ||
| PWID | 2 | 0.90 (0.15, 5.43) | 0.905 | 0.80 (0.13, 4.89) | 0.807 |
| MSM + PWID | 0 | (-) | (-) | (-) | (-) |
| Unknown/Other | 5 | 2.263 (0.52, 9.46) | 0.278 | 2.51 (0.59, 10.72) | 0.215 |
| Duration of HIV infection in years, median (IQR) | 5.4 (2.5–9.8) | 0.98 (0.95, 1.01) | 0.185 | 0.97 (0.93, 1.01) | 0.128 |
| Duration of HIV infection in years, n | |||||
| 0–1 | 21 | 1.39 (0.77, 2.51) | 0.277 | ||
| 1–5 | 28 | 1.46 (0.84, 2.53) | 0.176 | ||
| 5–10 | 32 | 1.39 (0.82, 2.37) | 0.221 | ||
| >10 | 26 | Ref | |||
| Initial referral to IDU | 17 | 1.21 (0.71, 2.01) | 0.486 | ||
| Duration of ART in years, median (IQR) | 4 (2.3–8.2) | 0.98 (0.95, 1.02) | 0.285 | ||
| CD4+ T cell count, cell/mm3, median (IQR) | 656 (486–826) | 1.00 (0.99–1.001) | 0.969 | ||
| CD4+ T cell count <200 cell/mm3, n | 3 | 0.47 (0.15, 1.49) | 0.199 | 1.67 (0.50, 5.57) | 0.403 |
| HIV RNA > 50 c/mL, n | 20 | 0.72 (0.44, 1.19) | 0.204 | 0.64 (0.36, 1.13) | 0.121 |
| History of syphilis, n | 59 | 0.77 (0.52, 1.13) | 0.181 | 1.06 (0.71, 1.60) | 0.768 |
OR, odds ratio; IQR, interquartile range; Ref, referent; MSM, men who have sex with men; PWID, people who inject drugs; HIV, human immunodeficiency virus; IDU, infectious diseases unit; ART, antiretroviral therapy; CD4, cluster of differentiation 4.
Stages of incident syphilis cases and treatment efficiency.
| Variable | n (%) |
|---|---|
| Stage of syphilis | |
| Early latent | 25 (23.4) |
| Late latent | 51 (47.7) |
| Primary | 10 (9.3) |
| Secondary | 20 (18.7) |
| Tertiary | 0 (0) |
| Neurosyphilis | 1 (0.9) |
| Treatment | |
| BPG | 92 (86) |
| Doxycycline | 14 (13.1) |
| Ceftriaxone | 1 (0.9) |
| Treatment success | |
| BPG | 89 (96.7) |
| Doxycycline | 13 (92.9) |
| Ceftriaxone | 1 (100) |
BPG, benzathine penicillin G.
References
1. Centers for Disease Control and Prevention. Sexually Transmitted Infections Surveillance, 2022; U.S. Department of Health and Human Services: Atlanta, GA, USA, 2022; Available online: https://www.cdc.gov/std/statistics/2022/default.htm (accessed on 14 May 2024).
2. European Centre for Disease Prevention and Control. Syphilis—Annual Epidemiological Report. 2022; Available online: https://www.ecdc.europa.eu/sites/default/files/documents/SYPH_AER_2022_Report_0.pdf (accessed on 11 May 2024).
3. World Health Organization. Global HIV Programme. HIV Data and Statistics. Epidemiological Fact Sheet. HIV Statistics, Globally and by WHO Region. 2023; Available online: https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0294-who-hiv-epi-factsheet-v7.pdf?sfvrsn=5cbb3393_7 (accessed on 14 May 2024).
4. Karp, G.; Schlaeffer, F.; Jotkowitz, A.; Riesenberg, K. Syphilis and HIV Co-Infection. Eur. J. Intern. Med.; 2009; 20, pp. 9-13. [DOI: https://dx.doi.org/10.1016/j.ejim.2008.04.002]
5. Ren, M.; Dashwood, T.; Walmsley, S. The Intersection of HIV and Syphilis: Update on the Key Considerations in Testing and Management. Curr. HIV/AIDS Rep.; 2021; 18, pp. 280-288. [DOI: https://dx.doi.org/10.1007/s11904-021-00564-z]
6. Lynn, W.; Lightman, S. Syphilis and HIV: A Dangerous Combination. Lancet Infect. Dis.; 2004; 4, pp. 456-466. [DOI: https://dx.doi.org/10.1016/S1473-3099(04)01061-8]
7. Wu, M.Y.; Gong, H.Z.; Hu, K.R.; Zheng, H.; Wan, X.; Li, J. Effect of Syphilis Infection on HIV Acquisition: A Systematic Review and Meta-Analysis. Sex. Transm. Infect.; 2021; 97, pp. 525-533. [DOI: https://dx.doi.org/10.1136/sextrans-2020-054706]
8. Solomon, M.M.; Mayer, K.H.; Glidden, D.V.; Liu, A.Y.; McMahan, V.M.; Guanira, J.V.; Chariyalertsak, S.; Fernandez, T.; Grant, R.M.; Bekker, L.-G. et al. Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex with Men in a Preexposure Prophylaxis Trial. Clin. Infect. Dis.; 2014; 59, pp. 1020-1026. [DOI: https://dx.doi.org/10.1093/cid/ciu450]
9. Ghanem, K.G.; Moore, R.D.; Rompalo, A.M.; Erbelding, E.J.; Zenilman, J.M.; Gebo, K.A. Neurosyphilis in a Clinical Cohort of HIV-1-Infected Patients. AIDS; 2008; 22, pp. 1145-1151. [DOI: https://dx.doi.org/10.1097/QAD.0b013e32830184df]
10. Ghanem, K.G.; Moore, R.D.; Rompalo, A.M.; Erbelding, E.J.; Zenilman, J.M.; Gebo, K.A. Antiretroviral Therapy Is Associated with Reduced Serologic Failure Rates for Syphilis among HIV-Infected Patients. Clin. Infect. Dis.; 2008; 47, pp. 258-265. [DOI: https://dx.doi.org/10.1086/589295]
11. González-López, J.J.; Guerrero, M.L.F.; Luján, R.; Tostado, S.F.; De Górgolas, M.; Requena, L. Factors Determining Serologic Response to Treatment in Patients with Syphilis. Clin. Infect. Dis.; 2009; 49, pp. 1505-1511. [DOI: https://dx.doi.org/10.1086/644618]
12. Lin, K.-Y.; Yang, C.-J.; Sun, H.-Y.; Chuang, Y.-C.; Chang, L.-H.; Liu, W.-C.; Su, Y.-C.; Chang, S.-Y.; Hung, C.-C.; Chang, S.-C. Comparisons of Serologic Responses of Early Syphilis to Treatment with a Single-Dose Benzathine Penicillin G Between HIV-Positive and HIV-Negative Patients. Infect. Dis. Ther.; 2021; 10, pp. 1287-1298. [DOI: https://dx.doi.org/10.1007/s40121-021-00450-6]
13. Genovese, G.; Nazzaro, G.; Coggi, A.; Gianotti, R.; Ramoni, S.; Cusini, M. Secondary Syphilis Masquerading as Lupus Vulgaris in an HIV-Infected Patient: A Diagnosis Suggested by Histology. Int. J. STD AIDS; 2018; 29, pp. 1454-1456. [DOI: https://dx.doi.org/10.1177/0956462418795590]
14. Yancheva, N.; Petrova, E.; Tchervenyakova, T. Atypical Secondary Syphilis Presentation in a Patient with Human Immunodeficiency Virus Infection: A Case Report. J. Med. Case Rep.; 2019; 13, 360. [DOI: https://dx.doi.org/10.1186/s13256-019-2291-5]
15. Stamm, L.V. Global Challenge of Antibiotic-Resistant Treponema Pallidum. Antimicrob. Agents Chemother.; 2010; 54, pp. 583-589. [DOI: https://dx.doi.org/10.1128/AAC.01095-09]
16. Tantalo, L.C.; Lieberman, N.A.P.; Pérez-Mañá, C.; Suñer, C.; Vall Mayans, M.; Ubals, M.; González-Beiras, C.; Rodríguez-Gascón, A.; Canut, A.; González-Candelas, F. et al. Antimicrobial Susceptibility of Treponema Pallidum Subspecies Pallidum: An in-Vitro Study. Lancet Microbe; 2023; 4, pp. e994-e1004. [DOI: https://dx.doi.org/10.1016/S2666-5247(23)00219-7]
17. Tsuboi, M.; Evans, J.; Davies, E.P.; Rowley, J.; Korenromp, E.L.; Clayton, T.; Taylor, M.M.; Mabey, D.; Chico, R.M. Prevalence of Syphilis among Men Who Have Sex with Men: A Global Systematic Review and Meta-Analysis from 2000–20. Lancet Glob. Health; 2021; 9, pp. e1110-e1118. [DOI: https://dx.doi.org/10.1016/S2214-109X(21)00221-7]
18. Fenton, K.A.; Breban, R.; Vardavas, R.; Okano, J.T.; Martin, T.; Aral, S.; Blower, S. Infectious Syphilis in High-Income Settings in the 21st Century. Lancet Infect. Dis.; 2008; 8, pp. 244-253. [DOI: https://dx.doi.org/10.1016/S1473-3099(08)70065-3]
19. Michaels, S.H.; Clark, R.; Kissinger, P. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection. N. Engl. J. Med.; 1998; 339, pp. 405-406. [DOI: https://dx.doi.org/10.1056/NEJM199808063390612]
20. Traeger, M.W.; Schroeder, S.E.; Wright, E.J.; Hellard, M.E.; Cornelisse, V.J.; Doyle, J.S.; Stoové, M.A. Effects of Pre-Exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. Clin. Infect. Dis.; 2018; 67, pp. 676-686. [DOI: https://dx.doi.org/10.1093/cid/ciy182]
21. Kidd, S.E.; Grey, J.A.; Torrone, E.A.; Weinstock, H.S. Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis—United States, 2013–2017. MMWR Morb. Mortal. Wkly. Rep.; 2019; 68, pp. 144-148. [DOI: https://dx.doi.org/10.15585/mmwr.mm6806a4]
22. Workowski, K.A.; Bachmann, L.H.; Chan, P.A.; Johnston, C.M.; Muzny, C.A.; Park, I.; Reno, H.; Zenilman, J.M.; Bolan, G.A. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm. Rep.; 2021; 70, pp. 1-187. [DOI: https://dx.doi.org/10.15585/mmwr.rr7004a1]
23. Janier, M.; Unemo, M.; Dupin, N.; Tiplica, G.S.; Potočnik, M.; Patel, R. 2020 European Guideline on the Management of Syphilis. J. Eur. Acad. Dermatol. Venereol.; 2021; 35, pp. 574-588. [DOI: https://dx.doi.org/10.1111/jdv.16946] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33094521]
24. Papp, J.R.; Park, I.U.; Fakile, Y.; Pereira, L.; Pillay, A.; Bolan, G.A. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm. Rep.; 2024; 73, pp. 1-32. [DOI: https://dx.doi.org/10.15585/mmwr.rr7301a1]
25. Menza, T.W.; Berry, S.A.; Dombrowski, J.; Cachay, E.; Dionne-Odom, J.; Christopoulos, K.; Crane, H.M.; Kitahata, M.M.; Mayer, K.H. Syphilis Testing and Diagnosis Among People with Human Immunodeficiency Virus (HIV) Engaged in Care at 4 US Clinical Sites, 2014–2018. Clin. Infect. Dis.; 2022; 75, pp. 483-492. [DOI: https://dx.doi.org/10.1093/cid/ciab944]
26. Chan, P.; Tang, T.H.C.; Kwong, R.T.S.; Chan, L.; Chan, H.S.Y.; Lam, K.W.; Ting, W.M.; Yung, S.K.; Lam, E.C.T.; Chu, M.Y. et al. Effects of Syphilis Infection among HIV-1-Positive Individuals on Suppressive Antiretroviral Therapy. AIDS Res. Ther.; 2022; 19, 69. [DOI: https://dx.doi.org/10.1186/s12981-022-00493-w]
27. Girma, S.; Amogne, W. Investigating Latent Syphilis in HIV Treatment-Experienced Ethiopians and Response to Therapy. PLoS ONE; 2022; 17, e0270878. [DOI: https://dx.doi.org/10.1371/journal.pone.0270878]
28. Coyer, L.; Prins, M.; Davidovich, U.; Van Bilsen, W.P.H.; Schim Van Der Loeff, M.F.; Hoornenborg, E.; Matser, A.; Boyd, A. Trends in Sexual Behavior and Sexually Transmitted Infections after Initiating Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Men Who Have Sex with Men from Amsterdam, the Netherlands: A Longitudinal Exposure-Matched Study. AIDS Patient Care STDS; 2022; 36, pp. 208-218. [DOI: https://dx.doi.org/10.1089/apc.2021.0219]
29. Begovac, J.; Romih Pintar, V.; Vrsaljko, N.; Močibob, L.; Bogdanić, N.; Zekan, Š.; Đaković Rode, O. Incidence, Risk Factors, and Clinical Findings of Syphilis among Men Living with HIV in Croatia during the COVID-19 Pandemic. Sci. Rep.; 2023; 13, 11784. [DOI: https://dx.doi.org/10.1038/s41598-023-38807-1]
30. Stanford, K.A.; Almirol, E.; Schneider, J.; Hazra, A. Rising Syphilis Rates During the COVID-19 Pandemic. Sex. Transm. Dis.; 2021; 48, pp. e81-e83. [DOI: https://dx.doi.org/10.1097/OLQ.0000000000001431]
31. Chang, J.J.; Chen, Q.; Dionne-Odom, J.; Hechter, R.C.; Bruxvoort, K.J. Changes in Testing and Diagnoses of Sexually Transmitted Infections and HIV During the COVID-19 Pandemic. Sex. Transm. Dis.; 2022; 49, pp. 851-854. [DOI: https://dx.doi.org/10.1097/OLQ.0000000000001639]
32. Callado, G.Y.; Gutfreund, M.C.; Pardo, I.; Hsieh, M.K.; Lin, V.; Sampson, M.M.; Nava, G.R.; Marins, T.A.; Deliberato, R.O.; Martino, M.D.V. et al. Syphilis Treatment: Systematic Review and Meta-Analysis Investigating Nonpenicillin Therapeutic Strategies. Open Forum Infect. Dis.; 2024; 11, ofae142. [DOI: https://dx.doi.org/10.1093/ofid/ofae142] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38595955]
33. Kimball, A.; Torrone, E.; Miele, K.; Bachmann, L.; Thorpe, P.; Weinstock, H.; Bowen, V. Missed Opportunities for Prevention of Congenital Syphilis—United States, 2018. MMWR Morb. Mortal. Wkly. Rep.; 2020; 69, pp. 661-665. [DOI: https://dx.doi.org/10.15585/mmwr.mm6922a1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32497029]
34. European Centre for Disease Prevention and Control. Technical Report. Developing a National Strategy for the Prevention and Control of Sexually Transmitted Infections. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/strategies-to-control-STIs.pdf (accessed on 16 May 2024).
35. Peterman, T.A.; Cha, S. Context-Appropriate Interventions to Prevent Syphilis: A Narrative Review. Sex. Transm. Dis.; 2018; 45, pp. S65-S71. [DOI: https://dx.doi.org/10.1097/OLQ.0000000000000804]
36. Jarzebowski, W. Effect of Early Syphilis Infection on Plasma Viral Load and CD4 Cell Count in Human Immunodeficiency Virus–Infected Men: Results From the FHDH-ANRS CO4 Cohort. Arch. Intern. Med.; 2012; 172, 1237. [DOI: https://dx.doi.org/10.1001/archinternmed.2012.2706]
37. Weintrob, A.C.; Gu, W.; Qin, J.; Robertson, J.; Ganeson, A.; Crum-Cianflone, N.F.; Landrum, M.L.; Wortmann, G.W.; Follman, D.; Agan, B.K. Syphilis Co-Infection Does Not Affect HIV Disease Progression. Int. J. STD AIDS; 2010; 21, pp. 57-59. [DOI: https://dx.doi.org/10.1258/ijsa.2009.009164]
38. Sadiq, S.T. The Effects of Early Syphilis on CD4 Counts and HIV-1 RNA Viral Loads in Blood and Semen. Sex. Transm. Infect.; 2005; 81, pp. 380-385. [DOI: https://dx.doi.org/10.1136/sti.2004.012914]
39. Mi, H.-F.; Shen, X.; Chen, X.-Q.; Zhang, X.-L.; Ke, W.-J.; Xiao, Y. Association between Treatment Failure in Patients with Early Syphilis and Penicillin Resistance-Related Gene Mutations of Treponema Pallidum: Protocol for a Multicentre Nested Case–Control Study. Front. Med.; 2023; 10, 1131921. [DOI: https://dx.doi.org/10.3389/fmed.2023.1131921]
40. Luetkemeyer, A.F.; Donnell, D.; Dombrowski, J.C.; Cohen, S.; Grabow, C.; Brown, C.E.; Malinski, C.; Perkins, R.; Nasser, M.; Lopez, C. et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N. Engl. J. Med.; 2023; 388, pp. 1296-1306. [DOI: https://dx.doi.org/10.1056/NEJMoa2211934]
41. Traeger, M.W.; Mayer, K.H.; Krakower, D.S.; Gitin, S.; Jenness, S.M.; Marcus, J.L. Potential Impact of Doxycycline Post-Exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections. Clin. Infect. Dis.; 2023; ciad488. [DOI: https://dx.doi.org/10.1093/cid/ciad488]
42. Truong, R.; Tang, V.; Grennan, T.; Tan, D.H.S. A Systematic Review of the Impacts of Oral Tetracycline Class Antibiotics on Antimicrobial Resistance in Normal Human Flora. JAC Antimicrob. Resist.; 2022; 4, dlac009. [DOI: https://dx.doi.org/10.1093/jacamr/dlac009]
43. Kenyon, C. Doxycycline Post-Exposure Prophylaxis Could Theoretically Select for Resistance to Various Antimicrobials in 19 Pathobionts: An In Silico Analysis. Int. J. Infect. Dis.; 2024; 142, 106974. [DOI: https://dx.doi.org/10.1016/j.ijid.2024.02.017]
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Pilalas, Dimitrios
; Tziovanaki, Theologia; Constanti, Margarita; Markakis, Konstantinos
; Pagioulas, Konstantinos; Papantoniou, Eleni
; Kapiki, Konstantina; Chrysanthidis, Theofilos; Kollaras, Panagiotis; Metallidis, Symeon; Tsachouridou, Olga